Semaglutide Breakthroughs: Heart, Kidney, and Weight Wins

In a landmark finding for obesity treatment, once-weekly subcutaneous semaglutide at 2.4 mg led to an average 14.9% reduction in body weight over 68 weeks when combined with lifestyle intervention. This is more than double the weight loss seen with placebo, representing a 12.4 percentage point advantage. The implications are profound: for a 200-pound person, this translates to nearly 30 pounds lost.

Even more encouraging, 86.4% of participants achieved at least 5% weight loss—a threshold linked to meaningful health improvements like better blood pressure and insulin sensitivity—while over half (50.5%) lost 15% or more. These results confirm semaglutide as one of the most effective pharmacologic tools for sustained weight management in people with obesity and cardiovascular risk.

The regimen was part of a comprehensive lifestyle program, underscoring that medication works best alongside behavioral support. This isn’t a quick fix—it’s a long-term strategy for metabolic health.

New analysis from the SELECT trial reveals that semaglutide doesn’t just help the heart and waistline—it also protects the kidneys. In adults with overweight or obesity and established cardiovascular disease (but no diabetes), once-weekly semaglutide 2.4 mg significantly slowed kidney function decline over the long term.

The study tracked a composite outcome including kidney failure, a sustained drop in eGFR of 50% or more, and death from kidney or cardiovascular causes. Results showed a clear protective effect, reinforcing semaglutide’s role in multi-organ defense, especially in high-risk populations.

This is critical because obesity and heart disease are major drivers of chronic kidney disease. By preserving kidney function, semaglutide may delay or prevent dialysis and reduce long-term healthcare burden. The mechanism likely involves weight loss, blood pressure reduction, and anti-inflammatory effects—all improved by the drug.

For the first time, a large trial has shown that semaglutide reduces major adverse cardiovascular events in adults with obesity who do not have diabetes. The study focused on individuals with preexisting heart disease, a group at high risk for heart attacks, strokes, and cardiovascular death.

Participants receiving once-weekly subcutaneous semaglutide at 2.4 mg experienced significantly fewer cardiovascular events compared to those on placebo—marking a pivotal shift in how we treat obesity-related heart risk. This suggests semaglutide’s benefits extend beyond weight loss to direct cardiovascular protection.

Key improvements included:

• Reduced inflammation (measured by lower C-reactive protein)
• Better blood pressure control
• Improved glycemic markers like HbA1c and fasting glucose
• Favorable lipid profile changes

These changes collectively lower atherosclerotic risk, making semaglutide a potential cornerstone in preventive cardiology for obese patients.

While semaglutide delivers impressive health benefits, it comes with a well-documented trade-off: gastrointestinal side effects. In clinical trials, nausea affected 44.2%, diarrhea 31.5%, and vomiting 24.8% of non-diabetic adults taking the 2.4 mg weekly dose. Most cases were mild to moderate and occurred early in treatment.

These symptoms typically subside over time as the body adjusts. Strategies like slow dose escalation, taking the injection with less food, and staying hydrated can help minimize discomfort. Still, 4.5% of participants discontinued treatment due to GI issues, compared to just 0.8% on placebo.

The high discontinuation rate underscores the need for patient education and support. Clinicians should set realistic expectations and monitor adherence, especially during the first few months. For many, the long-term benefits outweigh the temporary discomfort—but not all patients will tolerate the drug equally.

The EXSCEL trial offers important insights into the cardiovascular safety of once-weekly exenatide in adults with type 2 diabetes, particularly those with or at risk for heart failure. The study analyzed whether the drug influenced hospitalization rates for heart failure or other cardiovascular outcomes.

Results showed no significant increase or decrease in heart failure-related hospitalizations among patients taking exenatide, whether they had baseline heart failure or not. This suggests the medication is neutral—neither harmful nor protective—for heart failure risk in this population.

While not a breakthrough in efficacy, this safety profile is reassuring for clinicians considering exenatide as a treatment option for diabetic patients with cardiovascular comorbidities. It confirms that exenatide can be used without heightened concern for worsening heart failure, a common complication in type 2 diabetes.